Buserelin

Overview

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.

Indication

Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.

Associated Conditions

Endometriosis
Stage D2 Prostatic carcinoma

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial	2021/09/20	NCT05050084	Phase 3	Recruiting	NRG Oncology
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial	2020/08/14	NCT04513717	Phase 3	Recruiting	NRG Oncology
Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles	2013/03/22	NCT01816789	Phase 4	Terminated	Andros Day Surgery Clinic
Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders	2010/10/01	NCT01213147	Phase 4	Completed	Yazd Medical University
Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist	2009/01/28	NCT00830492	Phase 4	Completed	Yazd Research & Clinical Center for Infertility
Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH	2009/01/15	NCT00823602	Phase 3	UNKNOWN	Yazd Research & Clinical Center for Infertility
Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification	2009/01/15	NCT00823121	Phase 1	UNKNOWN	Yazd Research & Clinical Center for Infertility
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer	2008/04/02	NCT00651326	Phase 3	Terminated	NCIC Clinical Trials Group
Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles	2008/03/03	NCT00627406	Phase 4	Completed	Regionshospitalet Viborg, Skive
Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin	2007/04/18	NCT00461916	Phase 4	Completed	Tehran University of Medical Sciences

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access